Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMC is a specifically designed Chinese herbal formula investigated for the treatment of type 2 diabetes mellitus (T2DM) with hyperlipidemia. It has been shown to significantly alleviate hyperglycemia and hyperlipidemia, and to shift the gut microbiota structure in diabetic patients. AMC notably increases the abundance of beneficial bacteria such as *Blautia* spp. and *Faecalibacterium* spp., which are correlated with improvements in glucose and lipid homeostasis. Compared to metformin, AMC demonstrated better efficacies in improving homeostasis model assessment of insulin resistance (HOMA-IR) and plasma triglyceride levels, and exerted a larger effect on the gut microbiota.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AMC.